Fox Chase Cancer Center

 

Videos
09:27

Fox Chase Cancer Center

Pirtobrutinib in R/R B-Cell Malignancies: Newest Data From the BRUIN Trial

FEATURING Shazia Nakhoda
  • 18 views
  • December 13, 2024
06:32

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la/mUC), NIAGARA (MIBC), and Other Updates

FEATURING Elizabeth R. Plimack
  • 182 views
  • September 27, 2024
  • 3
12:50

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "The GIANT Trial (EA2186) - Gem & nab-Paclitaxel vs. 5-FU, Leucovorin, & Liposomal Irinotecan in Older Pts With Treatment-Naïve Metastatic Pancreatic Cancer"

FEATURING Efrat Dotan
  • 725 views
  • June 7, 2024
  • 3
04:25

Total Health

LS-SCLC Updates - 2023 ASCO® Direct Philadelphia

FEATURING Jessica Bauman
  • 82 views
  • September 29, 2023
04:35

Total Health

Chemo vs. Chemo + Pembro in 1L Pleural Mesothelioma - 2023 ASCO® Direct Philadelphia

FEATURING Jessica Bauman
  • 232 views
  • September 29, 2023
  • 2
26:42

Total Health

ADAURA & KEYNOTE-671 Trials: Early Stage NSCLC Updates - 2023 ASCO® Direct Philadelphia

FEATURING Jessica Bauman
  • 392 views
  • September 29, 2023
  • 3
06:11

Insights from 2023 EHA® Annual Meeting

EHA® 2023 Insights: "An Outpatient Model for Teclistamab Step-Up Dosing Administration - Initial Experiences at Fox Chase Cancer Center BMT Program"

FEATURING Asya Varshavsky-Yanovsky
  • 281 views
  • August 4, 2023
  • 3
21:34

2023 Texas Lung Cancer Conference Coverage

The Evolving Role of Dual Checkpoint Inhibition in Advanced NSCLC

FEATURING Hossein Borghaei
  • 118 views
  • May 25, 2023
03:05

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Adjuvant Therapies in Renal Cell Carcinoma: Are New Data Practice-Changing

FEATURING Matthew Zibelman
  • 264 views
  • March 1, 2023
  • 1
13:51

Fox Chase Cancer Center

Adjuvant Treatment of NSCLC: ADAURA in Context

FEATURING Martin Edelman
  • 550 views
  • December 28, 2022
  • 5
09:51

Fox Chase Cancer Center

Influence of 1L Chemo on Survival Outcomes of Patients with Advanced UC Who Receive 2L IO

FEATURING Ben Miron
  • 108 views
  • October 11, 2021
  • 1
08:35

Fox Chase Cancer Center

2L Treatment of Advanced Gastric Cancer: Moving Towards an Opportunity to Improve Survival

FEATURING Namrata Vijayvergia
  • 413 views
  • July 5, 2021
  • 2
19:53

Bladder Cancer Symposium: Update on Medical and Surgical Management for the Urologist

2021 Update on Advanced Urothelial Cancer: Navigating 1L and Beyond Treatment Options

FEATURING Elizabeth R. Plimack
  • 46 views
  • May 21, 2021
12:36

3rd Annual Atlanta Precision Oncology Symposium

Genotype-Directed Therapy for Advanced NSCLC: Overview of Targeted Therapy Efficacy Data for RET & MET Mutations

FEATURING Hossein Borghaei
  • 539 views
  • March 7, 2021
13:52

3rd Annual Atlanta Precision Oncology Symposium

Targeted Therapy for Advanced NSCLC: Efficacy Analysis of RET, KRAS, HER2 & BRAF Targeting Agents

FEATURING Hossein Borghaei
  • 35 views
  • March 7, 2021
34:34

UChicago Genetics in Clinical Cancer Care: From Family Reunions to the Frontline of Developmental Therapeutics

Immunology & IO in Lynch Syndrome: Immune System, MSI & Hereditary Mismatch Deficiency, Current Therapies & Immuno-Prevention

FEATURING Michael J. Hall
  • 111 views
  • February 16, 2021
  • 2
16:08

Fox Chase Cancer Center

Genomic Differentiation of Early-Onset CRC: When Should the Screening Start? How Do Mutations Appear and Increase? Does the Specific Mutation Matter?

FEATURING Joshua Meyer
  • 329 views
  • January 5, 2021
  • 3
08:15

2020 ASCO Virtual Direct™ Highlights

2020 Update on Radiation Therapy in Lung Cancer: Is High-Dose Twice-Daily TRT More Effective vs. Standard-Dose in LS-SCLC? Did Pembro + CCRT Show Promising Antitumor Activity in Unresectable Stage III NSCLC?

FEATURING Hossein Borghaei
  • 327 views
  • August 24, 2020
  • 3
10:59

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Targeted Therapy in NSCLC: Is Adjuvant Osimertinib Highly Effective and Practice Changing in Stage IB/II/IIIA EGFRm NSCLC After Complete Tumor Resection?

FEATURING Hossein Borghaei
  • 439 views
  • August 6, 2020
  • 1
03:24

Fox Chase Cancer Center

2020 ASCO Update on Advanced RCC: Pembrolizumab + Axitinib vs. Sunitinib - Which Drug Showed Greater Response in the 1st Line Advanced Disease? Did MK-6482 Show Clinical Activity in Clear Cell Disease?

FEATURING Elizabeth R. Plimack
  • 30 views
  • June 26, 2020
14:38

GRACE

The Role of IO in Bladder Cancer: Potential Benefits in Neoadjuvant Setting, Patient Selection & Metastatic Disease

FEATURING Elizabeth R. Plimack, Ramy Sedhom
  • 278 views
  • March 18, 2020
  • 2
10:57

23rd Collaborative Group of the Americas on Inherited Colorectal Cancer Annual Meeting

GI Cancer Risks Associated with Pathogenic Variants (PV) in the Ataxia Telangiectasia Mutated (ATM) Gene

FEATURING Michael Hall
  • 25 views
  • December 10, 2019
19:10

Fox Chase Updates in Bladder and Kidney Cancer 2019

2019 1st Line Systemic Therapy for Metastatic Urothelial Carcinoma: Cisplatin as SoC, Pembro Mono as Alternative for Cis-Ineligible, Chemo +/- Atezolizumab vs. Atezolizumab Alone, Enfortumab Vedotin + Pembro, and Subsequent Therapies

FEATURING Elizabeth R. Plimack
  • 444 views
  • November 22, 2019
  • 4
14:23

Fox Chase Cancer Center

Front Line Therapy in NSCLC: Immunotherapy vs Immunotherapy + Chemo?

FEATURING Hossein Borghaei
  • 228 views
  • August 22, 2018
20:36

Fox Chase Cancer Center

I-O/Chemo Combination Therapies in NSCLC

FEATURING Hossein Borghaei
  • 298 views
  • August 22, 2018
  • 2
09:14

Fox Chase Cancer Center

Second Line Treatment Options in NSCLC

FEATURING Hossein Borghaei
  • 394 views
  • July 9, 2018
  • 1